DARE Dare Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401914 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,570.3%
TTM net income YoY39.4%
TTM EPS YoY66.7%
Revenue 3-yr CAGR12.2%
Net income 3-yr CAGR—
Margins
Gross margin26.4%
Operating margin-746.1%
Net margin-749.8%
FCF margin-1,279.2%
EBITDA margin-592.2%
Returns
ROE-407.1%
ROA-40.0%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets89.4%
Debt / equity0.00x
Current ratio1.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio26.4%
Payout ratio—
Capex / revenue34.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.03M | $9,784 | $2.81M | $10.00M | $0 |
| Cost of revenue | $295,799 | $0 | — | — | — |
| Gross profit | $734,394 | $9,784 | — | — | — |
| R&D expense | $5.52M | $14.31M | $21.54M | $30.04M | $30.62M |
| SG&A expense | $8.76M | $9.16M | $12.11M | $11.24M | $8.35M |
| Operating income | -$13.55M | -$23.45M | -$30.94M | -$31.39M | -$39.07M |
| Pretax income | -$13.54M | -$4.05M | -$30.16M | -$30.95M | -$38.70M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.40M | -$4.05M | -$30.16M | -$30.95M | -$38.70M |
| EBITDA | -$11.92M | -$23.41M | -$30.90M | -$31.36M | -$39.04M |
| EPS (basic) | -1.20 | -0.48 | -4.15 | -0.37 | -0.63 |
| EPS (diluted) | -1.20 | -0.48 | -4.15 | -0.37 | -0.63 |
| Weighted avg. shares (diluted) | 11.18M | 8.50M | 7.28M | 84.57M | 61.15M |
| Balance sheet | |||||
| Cash & equivalents | $24.71M | $16.00M | $10.81M | $34.67M | $51.67M |
| Receivables | — | — | — | — | $0 |
| Current assets | $27.06M | $18.45M | $17.54M | $43.04M | $55.30M |
| PP&E, net | $1.56M | $1.34M | $655,975 | $64,908 | $26,041 |
| Total assets | $32.47M | $22.10M | $21.28M | $43.83M | $55.81M |
| Current liabilities | $23.69M | $21.61M | $20.48M | $31.62M | $16.05M |
| Short-term debt | — | $4,054 | — | — | — |
| Total liabilities | $29.63M | $28.11M | $26.33M | $32.71M | $17.05M |
| Shareholders' equity | $2.84M | -$6.01M | -$5.05M | $11.11M | $38.75M |
| Shares outstanding | 14.50M | 8.70M | 8.33M | 84.83M | 83.94M |
| Cash flow statement | |||||
| Operating cash flow | -$9.89M | $5.47M | -$38.86M | -$18.09M | -$28.76M |
| Capital expenditure | $385,278 | $573,046 | $629,430 | $63,069 | $14,524 |
| Free cash flow | -$10.27M | $4.90M | -$39.49M | -$18.15M | -$28.78M |
| Investing cash flow | -$385,278 | -$573,046 | -$629,430 | -$63,069 | -$14,524 |
| Financing cash flow | $19.28M | $354,522 | $15.64M | $1.34M | $75.85M |
| Depreciation & amortization | $1.63M | $42,325 | $38,363 | $24,202 | $26,413 |
| Stock-based compensation | $1.50M | $2.20M | $2.53M | $2.16M | $1.60M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.